News

Event: Community Involvement in TB Drug Development: A roundtable discussion


23 May 2010
by Working Group

A Satellite Session at the 2nd TB Conference
June 3, 2010; 16:00 – 18:00
MR 11, ICC, Durban

Community engagement in TB drug research is growing practice, made possible by the fact that several new drug candidates are entering clinical trials. This roundtable will provide a forum for dialogue between researchers, community members, CBOs/NGOs, and advocates about methods for effective community engagement in TB research. Panelists representing several viewpoints will highlight successful practices for encouraging stakeholder involvement in research and discuss how communities can influence national policies and procedures to ensure the rapid adoption and roll-out of new TB regimens, once available.


Moderator:
Javid Syed, Treatment Action Group

Panel Presentations:

  • Research Literacy: A fundamental component of community engagement — Paula Akugizibwe, AIDS Rights Alliance South Africa (invited)
  • Community Outreach: A researcher’s perspective — Dr. Gavin Churchyard, Aurum Institute
  • Best Practices for Community Engagement in TB Drug Research — Dr. Jane Ong’ang’o, Kenya Medical Research Institute
  • Working with Local Government — Doctor Nuglube, Lusaka University Teaching Hospital Community Advisory Board
  • Advocacy for Policy Change — Nathan Geffen, Treatment Action Campaign

Panel presentations will be followed by open discussion. Light refreshments will be provided.

To indicate your interest in attending, please email rsvp@tballiance.org


TB Alliance
Sponsored by the TB Alliance

More News
22 Jul 2024
The National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) has issued a $30.8 million grant to the Preclinical Design and Clinical Translation of TB Regimens (PreDiCTR) consortium , a new consortium co-led by investigators from Weill Cornell Medicine; the...
27 Jun 2024
On May 17, the World Health Organization (WHO) released its updated  Bacterial Priority Pathogens List (BPPL) 2024 and for the first time in its history it included a drug resistant strain of Mycobacterium tuberculosis. Along with three other new families of antibiotic-resistant bacterial pathogens...
19 Mar 2024
For World TB Day 2024, the WGND is spotlighting a monumental achievement in TB drug research and development: the Global TB Drug Pipeline has never been bigger than it is today. The number of drug candidates being clinically evaluated for use in the treatment of adult pulmonary TB has surpassed...